Navigation Links
Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes
Date:6/26/2010

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular (CV) events associated with SYMLIN® (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

The meta-analysis included five completed, randomized, controlled clinical trials of 16 to 52 weeks' duration, and was based on the U.S. Food and Drug Administration's (FDA's) recent guidance for evaluating CV risk in new type 2 diabetes agents. The primary endpoint for this analysis was occurrence of primary major adverse CV events (MACE). The 95 percent confidence interval for the estimated risk ratio for the primary endpoint was 0.55 to 1.34.  With the upper limit below the FDA-specified threshold of 1.8, this suggests that there is no increase in CV risk associated with SYMLIN use.  

"People with diabetes are two to four times more likely to develop cardiovascular disease because of increased risk factors such as high blood pressure, lipid disorders and obesity," said Orville G. Kolterman, M.D., senior vice president, chief medical officer at Amylin. "SYMLIN is an important tool for many patients who struggle to achieve their glucose control targets, despite their best efforts with insulin. These safety analyses confirm our findings from individual clinical studies and provide additional insight into the CV safety prof
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
2. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
3. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
4. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
5. Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting
6. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
7. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
8. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
9. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
10. Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
11. Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015   Intrexon Corporation ... biology, announced today the appointment of Olivier ... Consumer Sector.  Mr. Jarry will lead the expansion ... and applications for consumer markets.  ... of experience in leading global life sciences and ...
(Date:6/2/2015)... , June 2, 2015  Alere Inc. ... rapid diagnostics, joined the White House Antibiotic Stewardship ... commitments to support and advance the President,s National ... commitments include a number of measurable goals and ... achieved, will help healthcare providers protect their patients ...
(Date:6/2/2015)... 02, 2015 German-based Moenninghoff has designated ... distributor for the Moenninghoff product line . ... pleased to announce that the R.M. Hoffman Company will ... firm, founded in 1916, this is a strategically important ... the kind of professional distributor we need to successfully ...
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
Breaking Biology Technology:Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2
... researchers have created ,bacterial computers, with the potential ... the research, published in BioMed Central,s open access ... computing in living cells is feasible, opening the ... bacterial computers illustrate the feasibility of extending the ...
... Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... prospectus with the securities commissions of British Columbia and ... S-3 with the United States Securities and Exchange Commission ... final and / or declared effective, will allow Angiotech ...
... , ANAHEIM, Calif., July 23 Varian ... spectrum of new and updated products that improve and simplify the ... will be a new version of the Eclipse(TM) radiotherapy treatment planning ... and clinical flexibility. The new software release received FDA 510(k) ...
Cached Biology Technology:Genetically engineered bacteria compute the route 2Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement 2Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement 3Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement 4Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting 2Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting 3Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting 4
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... of Tufts graduate students have won $10,000 from ... their research into solutions to some of the world,s ... of renewable energy, and the creation of ,green, medical ... of universities that participate annually in the global competition ...
... ,bio-derived, Australian and New Zealand aviation fuels industry ... compiled by CSIRO in collaboration with the region,s ... Sustainable Aviation, predicts that over the next 20 ... industry could cut greenhouse gas emissions by 17 ...
... teeth discovered in Inner Mongolia are a new species of ... much older than previously reported, according to paleontologist Yuri Kimura ... new species were discovered in sediments that are 17 million ... named it Sicista primus to include the Latin ...
Cached Biology News:Tufts graduate students receive $10,000 prizes 2Sustainable 'bio-derived' jet fuel industry is achievable 2Birch mouse ancestor discovered in Inner Mongolia is new species of rare 'living fossil' 2Birch mouse ancestor discovered in Inner Mongolia is new species of rare 'living fossil' 3Birch mouse ancestor discovered in Inner Mongolia is new species of rare 'living fossil' 4
... LDL (Competitive) EIA Principle: The Oxidized ... antibody 4E6. Oxidized LDL in the sample competes ... to the microtiter well for the binding of ... st Sample Size: 25 l The ...
... diluent that is designed for use with HRP ... with a mouse monoclonal coating antibody. ... proteins to prevent non-specific binding between the coating ... This buffer may be used to stabilize newly ...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
Request Info...
Biology Products: